Overview

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Status:
RECRUITING

Trial end date:
2027-02-28

Target enrollment:

Participant gender:

Summary

This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

Phase:

PHASE3

Details

Lead Sponsor:

Allist Pharmaceuticals, Inc.

Treatments:

Carboplatin
Pemetrexed
tislelizumab